News Early Clovis approval notches up competition in ovarian canc... Clovis' Rubraca will compete against AstraZeneca rival.
News Roche's Mabthera faces cut-price competition in EU Blockbuster likely to face cheap near-copy for first time.
News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
Partner Content Partner Content pharmaphorum and Symplur launch Conference360 Report pharmaphorum media and Symplur, LLC launch Conference360 Report to help pharma and other stakeholders understand social media conversations around medical congresses
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
